enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Biogen-UCB's lupus drug meets main goal of late-stage trial - AOL

   www.aol.com/news/biogen-ucbs-lupus-drug-meets...

   Biogen and Belgian partner UCB said on Tuesday their experimental lupus treatment met the main goal of a late-stage trial in patients with the chronic disease, a surprise result after the drug ...

3. Belimumab - Wikipedia

   en.wikipedia.org/wiki/Belimumab

   Belimumab is primarily used in people with systemic lupus erythematosus. When it was introduced in 2011, it was the first new drug approved to treat lupus in 56 years. [8] Sales rose to $31.2 million in the first quarter of 2012. [37] The total cost for the first year of treatment with belimumab is $28,000. [38]

4. Roivant Sciences' lupus drug fails to reduce symptoms in mid ...

   www.aol.com/news/roivant-sciences-lupus-drug...

   The oral drug, brepocitinib, did not meet the primary study goal of reduction in disease activity at week 52 in patients of SLE, in which the immune system that normally helps protect the body ...

5. Anifrolumab - Wikipedia

   en.wikipedia.org/wiki/Anifrolumab

   Anifrolumab, sold under the brand name Saphnelo, is a monoclonal antibody used for the treatment of systemic lupus erythematosus. [5] [7] It binds to the type I interferon receptor, blocking the activity of type I interferons such as interferon-α and interferon-β.

6. AstraZeneca lupus drug shows promise after set-back last year

   www.aol.com/news/astrazeneca-lupus-drug-meets...

   The British drugmaker said anifrolumab under the TULIP 2 program helped patients with systemic lupus erythematosus, commonly known as SLE. The drug had failed to meet its main goal in the final ...

7. Litifilimab - Wikipedia

   en.wikipedia.org/wiki/Litifilimab

   Litifilimab is an investigational drug being evaluated for the treatment of cutaneous lupus erythematosus and systemic lupus erythematosus. It is an anti- BDCA2 monocolonal antibody. [ 1 ] [ 2 ] [ 3 ]

8. Obexelimab - Wikipedia

   en.wikipedia.org/wiki/Obexelimab

   Obexelimab is an experimental drug developed to treat IgG4-related disease and lupus. It works as a "bifunctional, non-cytolytic, humanised monoclonal antibody that binds CD19 and Fc gamma receptor IIb to inhibit B cells, plasmablasts, and CD19-expressing plasma cells." [1] [2]

9. 'Lifesaving' lupus drug in short supply after Trump touts ...

   www.aol.com/news/lifesaving-lupus-drug-short...

   For premium support please call: 800-290-4726 more ways to reach us